Small molecule · Cytotoxic · developed by Aclaris
A-101 is a topical formulation of high-concentration hydrogen peroxide with keratolytic activity. It penetrates skin cells, generates reactive oxygen species, induces oxidative stress and apoptosis to clear affected skin. It is studied for seborrheic keratosis, common warts, and dermatosis papulosa nigra.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03487588 | Phase 4 | Seborrheic Keratosis | Completed | ACRS |
| NCT03812510 | Phase 3 | Common Wart | Completed | ACRS |
| NCT02667288 | Phase 3 | Seborrheic Keratosis | Completed | ACRS |
| NCT03224598 | Phase 2 | Dermatosis Papulosa Nigra | Completed | ACRS |
| NCT02669862 | Phase 2 | Common Warts | Completed | ACRS |
| NCT02160626 | Phase 2 | Seborrheic Keratosis | Completed | ACRS |
| NCT01986920 | Phase 1/2 | Seborrheic Keratosis (SK) | Completed | ACRS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Common WartDermatosis Papulosa NigraSeborrheic KeratosisSeborrheic Keratosis (SK)
Updated Oct 3, 2026. Something wrong or missing? Report it on the ACRS page.
See ACRS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ACRS catalysts and pipeline →